News Hub | News Direct

Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive shared significant news regarding the regulatory approval for Medicare reimbursement of their oral medical devices designed for sleep apnea treatment. Huntsman emphasized the unique design of Vivos's medical devices, which are capable of enhancing the human airway and potentially eliminating sleep apnea symptoms after a 12-month treatment period. This FDA clearance positions Vivos as the only line of oral medical devices globally that can treat severe sleep apnea. The approval for Medicare reimbursement is described as a monumental achievement, as it is expected to benefit tens of millions of Medicare patients suffering from moderate to severe obstructive sleep apnea (OSA) without the need for lifetime intervention. This recognition by the Centers for Medicare and Medicaid Services (CMS) propels Vivos's devices as a viable alternative to traditional CPAP treatments, especially timely given the recent recalls in the CPAP market and Philips' withdrawal from the U.S. market. Huntsman expressed his excitement about the broader implications of this approval, including increased recommendations of Vivos's treatments by medical and dental providers and a growing awareness of their efficacy as an alternative to CPAP treatments. This development represents a significant step forward in transforming patient care for individuals suffering from sleep apnea. Watch the full interview to learn more about Vivos Therapeutics Inc.'s pioneering approach to treating sleep apnea and their vision for improving patient care. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 09, 2024 11:45 AM Pacific Daylight Time

Video

FITPAL LLC Announces a Holistic Approach to Health Management: Combining GLP-1 Treatments, DEXA Scans, and Digital Health Tools

Rev Up Marketers

FITPAL LLC is proud to announce a comprehensive approach to health management that combines GLP-1 treatments, DEXA scans, and its innovative Fitpal Pro App. This program goes beyond traditional methods by focusing on a multifaceted approach to wellness, equipping individuals with the tools and knowledge they need to achieve their health goals. GLP-1 Treatments: A Promising Avenue for Metabolic Health Glucagon-like peptide-1 (GLP-1) treatments have emerged as a significant advancement in managing metabolic health. GLP-1 receptors are naturally found in the gut and pancreas, and GLP-1 drugs mimic the effects of the GLP-1 hormone. These treatments have been shown to improve glycemic control, increase satiety, and potentially offer other cardiovascular benefits. When incorporated into a personalized healthcare plan, these treatments can be a valuable tool for individuals seeking to manage blood sugar levels and support overall metabolic health. However, it is crucial to consult with a healthcare professional to determine if GLP-1 treatment is suitable for each specific case. DEXA Scans: Providing Insights into Body Composition DEXA scans, also known as dual-energy X-ray absorptiometry scans, are a type of bone density scan that offers valuable insights into body composition. They measure bone mineral density (BMD), which is a crucial indicator of bone health. Additionally, they can differentiate between bone mass, muscle mass, and body fat percentage. By providing a detailed dexa body composition analysis, these scans can be instrumental in guiding treatment plans and monitoring progress. For instance, they can help assess the effectiveness of weight management programs or track changes in muscle mass over time. Fitpal Pro App: A Digital Health Tool to Empower Individuals The Fitpal Pro App serves as the cornerstone of this comprehensive health management program. This App provides users with personalized meal plans, calorie tracking tools, and fitness routines tailored to their individual needs and goals. The app also integrates with wearable devices to monitor activity levels and sleep patterns, providing valuable insights into overall health and well-being. A Symbiotic Relationship: Combining Technologies for Optimal Health The unique combination of GLP-1 treatments, DEXA scans, and the Fitpal Pro App fosters a symbiotic relationship that empowers individuals to take a proactive approach to their health. GLP-1 treatments can support metabolic health, while DEXA scans provide valuable insights into body composition. The Fitpal Pro App serves as a central hub, allowing users to track progress, access educational resources, and stay connected with their healthcare providers. This initiative by FITPAL LLC signifies a shift towards a more holistic approach to health management, focusing on personalized care and providing individuals with the knowledge and resources they need to thrive. For any press-related queries or additional details, please mail to support@fitpal.com or visit https://fitpal.com/. Groupon: https://www.groupon.com/deals/fitpal-l Contact Details Fitpal LLC Media Relations +1 646-437-8646 support@fitpal.com Company Website https://booking.fitpal.com/

April 09, 2024 02:07 PM Eastern Daylight Time

Image

From AI To Foodtech, OurCrowd Brings More Opportunities To Investors With Three New Funds

OurCrowd

By Meg Flippin, Benzinga When it comes to transformative, revolutionary technology, AI is high on the list. After all, it impacts everything from how we craft research papers and emails to what we eat. It is also driving unprecedented deal-making with investment dollars pouring into AI and generative AI at a fast clip, with those investments also naturally spilling over into other impacted sectors like foodtech. OurCrowd, the leading global digital investment firm, captures all of those opportunities and more with three popular investment funds: The OurCrowd AI Fund, The OurCrowd FoodTech Fund and OC50 VIII. Through these funds, investors get access to the startups OurCrowd is making bets on in fast-growing markets like AI, foodtech and software-as-a-service, to name a few. Declared Israel’s “most active investor” for the past 10 years by PitchBook, OurCrowd has recorded 63 exits from 440 portfolio companies since its inception in 2013 and is invested in 410 additional companies via partner funds. It has more than 230,000 registered investors from 195 countries among its members. Through the OurCrowd platform, accredited investors can participate in a wide range of deals from individual startups to highly diversified funds, private equity, venture debt and other hard-to-access private market opportunities. OurCrowd gives investors access to multiple funds based on sector, stage, geography or investment thesis. Generative AI Transforming The World The OurCrowd AI Fund is one example of the types of opportunities OurCrowd offers. The $50 million fund seeks appreciation by investing in 20 to 25 AI startups on the OurCrowd platform using AI, generative AI and machine learning to positively impact multiple industries and sectors. The fund is focused on companies developing generative AI across several sectors, including medtech, mobility, agtech, cybersecurity, foodtech, climatech, legaltech and fintech. The fund will also invest in companies that provide AI solutions to support key business categories across technology sectors, including customer operations, marketing and sales, software engineering and R&D. OurCrowd sees a big opportunity for the startups operating in the generative AI space, pointing to ChatGPT to underscore the potential. “Since the release of OpenAI’s ChatGPT in November 2022 the interest in artificial intelligence (AI) and particularly in generative AI has surged. The remarkable success of ChatGPT is a testament to the power of product/market fit,” OurCrowd wrote in its investment prospectus for the fund. “Launched on November 30, 2022, it gained over 1 million users in just 5 days and reached 100M users in just 2 months. This level of mass adoption for a technology product is unprecedented, way outpacing previous tech innovative waves such as the PC (it took Apple 14 years and Microsoft 10 years to attain 100M users), Internet (Amazon – 12 years, Facebook 5 years and Google raised the bar to 1 year), Mobile (Instagram – 30 months and TikTok – 9 months).” To learn more about the OurCrowd AI Fund and to invest, click here. Technology Changing The Way We Eat Foodtech is another area OurCrowd is bullish about and so it has launched the OurCrowd FoodTech Fund. The fund is raising $30 million to invest in 15 to 20 food technology companies offered on the OurCrowd platform. OurCrowd says the foodtech market is booming, with a few areas of the market dominating, including bioengineering alternative proteins, supply-chain optimization, AI-driven smart home cooking products and delivery apps. The OurCrowd FoodTech Fund invests in a wide range of technology companies seeking to tackle the challenge of feeding the world’s fast-growing population while decarbonizing the global economy. Companies in the fund will also address new trends in culinary preferences, as well as lifestyle pressures and sustainability demands among Millennials and Generation Z. OurCrowd knows a thing or two about foodtech, which is what it says makes its fund attractive to accredited investors. The VC firm has invested more than $102 million across 20 foodtech companies worldwide, including Beyond Meat Inc. (NASDAQ: BYND), which had a successful IPO in 2019. Of its investments, nine are in Israel, which is a global leader in the number of alternative protein startups and amount invested, second only to the U.S. OurCrowd says it’s well positioned to leverage Israel’s cutting-edge leadership in the space via its network of entrepreneurs, scientists, third-party funds and dedicated in-house food and agtech incubators in Israel and New Zealand. Moreover, since 2021, OurCrowd has been among the ten most active VCs globally in foodtech, according to PitchBook data. To learn more about the OC FoodTech fund and how to invest click here. VC Access Through OurCrowd’s OC50 VIII Fund With so many startups in AI, foodtech and other areas of technology, it's not surprising that a lot of deal-making is going on. OurCrowd is giving investors access to that via its hyperdiversified OC50 VIII fund. Through the fund, investors get unprecedented broad exposure to the venture capital asset class across technology sectors where OurCrowd professionals have developed particular expertise, geographies where OurCrowd has developed networks of investors and global partners and across all development stages of startup companies from early-stage to pre-IPO. The investments cover several areas of tech including software-as-a-service (SaaS), fintech, medtech and digital health, mobility, cybersecurity and consumer and enterprise hardware. OurCrowd is leveling the playing field with the fund, giving investors access to venture deals long reserved only for institutional investors and elite VCs – offering instant diversification, rapid deployment of funds, earlier distributions and preferential access to the OurCrowd platform’s top deals. To invest in the OC50 VIII fund and learn more about its strategy click here. Beyond AI And Tech OurCrowd isn’t only focusing on AI and food tech, it's also adapting to geopolitical unrest, recently launching the $50 million Israel Resilience Fund. The fund is focused on startups that are directly affected by the Israeli/Hamas conflict or are developing solutions to address the environmental impact, emergency medicine, food security, cybersecurity, media monitoring, reconstruction and other verticals. That fund closed its first round 40 days after announcing, with $13 million in capital commitments. It's one of the fastest-closing venture funds to go from conception to closure and eight actual investments, according to OurCrowd. The fund plans to invest in about 40 companies and has so far helped to unlock more than $100 million in matching funds from other investors and government bodies. For an opportunity to get in early on the Israeli companies making a difference despite the Israeli/Hamas conflict click here. Change is happening at a dizzying pace driven by AI, generative AI and machine learning. Through these funds from OurCrowd, investors get early access to up-and-coming startups that have the potential to be the leaders of tomorrow. Click here to begin investing with OurCrowd. Featured photo by Steve Johnson on Unsplash. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

April 09, 2024 08:45 AM Eastern Daylight Time

Image

hVIVO achieves record revenue and initiates dividend policy following successful year

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin increase from 18.7% to 23.3%, surpassing prior guidance. The company's absolute EBITDA rose to £30 million, a 44% increase from the previous year. Khan attributed the success to hVIVO conducting more human challenge trials, leading to improved patient recruitment efficiency and better utilisation of facilities and staff. Despite challenges such as MHRA delays, significant funding for a new Canary Wharf facility positively impacted the financial results. hVIVO also initiated an annual dividend policy, planning a £1.4 million dividend distribution following a strong cash generation year. The Canary Wharf facility's development, notably ahead of schedule, includes a 50-bed quarantine facility and a laboratory, set to be fully operational by the end of July. This expansion is expected to enhance operational efficiency, increase revenue potential to up to £95 million, and strengthen hVIVO's position in the human challenge trial industry globally. For 2024, the company anticipates hitting a £62 million revenue target, with £180 million in the weighted order book ensuring a robust pipeline. Despite a study cancellation, hVIVO remains confident in its revenue and EBIT margin targets. Looking forward, hVIVO aims for a £100 million revenue target by 2028, driven by expanding its human challenge trials, increasing clinical trial services, and exploring M&A activities, supported by a strong cash reserve. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 09, 2024 07:51 AM Eastern Daylight Time

Video

Genflow Biosciences attracts new institutional investors with £715,000 fundraise

Genflow Biosciences PLC

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire tells Proactive's Stephen Gunnion the company has successfully raised £715,000 through a mix of placements and subscriptions for new stock. This fundraising effort was notably supported by company directors, including Leire, and new institutional investors. Leire highlighted the importance of this move as a strategic effort to stabilise and grow the company, especially noting the significance of attracting institutional investment. Historically, Genflow relied on grants and research funding, making this step a notable shift in its funding strategy. Leire also mentioned the company's focus on longevity and healthspan, pointing out the increasing gap between lifespan and healthspan as a major healthcare and economic challenge. Genflow's approach to addressing age-related diseases has started to attract attention from the institutional market, recognizing the potential high upside in the longevity sector. The funds raised are earmarked for continuing clinical trials in their three main programs: progeria, non-alcoholic steatohepatitis (NASH), and sarcopenia, aiming to reduce both financial and scientific risks by diversifying their portfolio. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 08, 2024 11:13 AM Eastern Daylight Time

Video

FendX Technologies Innovates Surface Protection with Nanotechnology

FendX Technologies Inc

FendX Technologies CEO Carolyn Myers joined Steve Darling from Proactive to share updates about FendX Technologies, a company pioneering the development of nanotechnology-based products designed to protect high-touch surfaces from contamination. Myers explained that FendX's innovations, licensed from McMaster University nearly four years ago, are focused on creating surfaces to which bacteria, viruses, and organic substances do not adhere, boasting efficacy rates of 95% or higher. These products include a film with an adhesive backing for easy application and a spray offering broader application, both providing 24-hour protection against contaminants. The company is targeting the healthcare sector, particularly hospitals and long-term care facilities, as well as high-traffic areas such as transportation hubs, schools, and malls. The goal is to mitigate the transmission of potentially lethal pathogens in these environments. Following a recent private placement, FendX is gearing up for the commercialization of its REPELWRAP Film and advancing the spray to be commercialized in 2025. Ongoing developments in the product lineup are also underway to further combat surface contamination. Overall, FendX Technologies is focused on leveraging nanotechnology to create innovative solutions for surface protection, aiming to contribute to public health and safety in various sectors. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 08, 2024 07:38 AM Eastern Daylight Time

Video

Non-addictive options to Opioids: Exploring Pain Relief Options Before Taking Opioids

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/RjjYJwM-XFc While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries. The U.S. makes up only 4.4% of the world’s population, but it consumes over 80% of the world’s opioids Luckily, consumers today have more options than ever before for powerful, nonaddictive pain relief as they navigate their unique positions on the overall pain spectrum, including but not limited to over-the-counter (OTC) medications, physical therapy, medication and chiropractic care. Mothers Against Prescription Drug Abuse (MAPDA) in partnership with Aleve®, a marquee pain relief product from Bayer indicated for minor pain, launched “The Painful Truth,” campaign developed to encourage consumers to explore, with their doctors, pain relief options such as OTC products before taking opioids, when appropriate. “The Painful Truth” campaign launched with a film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance. The featured patients believe they are participating in a video call with a pain expert who will help them explore their options, but as the conversation progresses, our “expert” reveals that they are in fact in recovery from opioid use disorder. At this critical juncture in their care, the patients are encouraged to consider different pain relief options. A nationwide media tour was conducted on March 26th featuring Mary Bono, Co-Founder, Chair of the Board of Directors & CEO of Mother’s Against Drug Abuse (MAPDA) and Matt Robinson, A voice from “The Painful Truth” campaign and Co-Host of Till the Wheels Fall Off (TWFO) podcast. Topics that were discussed included: · What people need to know about the pain relief options available to them before taking opioids when appropriate and after discussion with their healthcare provider. · Matt’s first-person experience with opioid use disorder. · The work Mother’s Against Drug Abuse has done to address the issue. · How patients can choose and advocate for themselves as it relates to pain management. For more information, visit aleve.com/thepainfultruth. About with Mothers Against Prescription Drug Abuse (MAPDA) Founded in 2011, Mothers Against Prescription Drug Abuse is a nationally recognized 501(c)(3) nonprofit organization focused on policy advocacy, opioid use disorder (OUD) prevention education, and opioid awareness programs. For more information, visit mapda.net. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

April 05, 2024 10:39 AM Eastern Daylight Time

Video

Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform

Benzinga

By Jeremy Golden, Benzinga Approximately two million people were diagnosed with cancer in the U.S. in 2023, with breast, prostate, lung and bronchus cancers among the most common. An estimated 609,820 people died of cancer last year. The most common treatments are surgery, chemotherapy and radiation, though other options include targeted therapy as well as laser and hormonal therapies. Another treatment option is immunotherapy, which is designed to utilize the immune system to fight cancer. Immune responses are orchestrated by key immune cells in the lymph nodes, but for many therapies, getting to these critical sites is far from certain. Small molecule-based immunomodulators easily pass through the blood vessel walls at the injection site. As a result, they are rapidly flushed away into the systemic circulation, limiting access to the lymph nodes. Often, this results in a failure to realize the full potential of the immune response. Worse yet, it can lead to the development of dangerous toxicities at other sites in the body. Elicio Therapeutics’ Novel Approach Founded in 2011, Elicio Therapeutics, Inc. (NASDAQ: ELTX) is developing treatment options aimed at significantly improving the quality of life for cancer patients through the utilization of precision vaccines, immunomodulators and cell-based therapies to potentially assemble cancer-killing immune responses against solid tumors. The company is optimistic about the potential of lymph node-targeting made possible by applying the natural trafficking pathways of larger molecules. This approach differentiates Elicio from its competitors and could be highly promising for enhancing anti-tumor immune responses and improving therapeutic efficacy. Developed at the Massachusetts Institute of Technology (MIT), the company’s proprietary Amphiphile or “AMP” platform, which combines expertise in materials science and immunology, is being used to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases. Here’s how it works: The AMP platform is designed to deliver therapeutic payloads directly to critical immune cells in the lymph nodes, enhancing the cancer-fighting mechanisms of the immune system. By delivering cancer immunotherapies to the center of the immune response, this approach is intended to optimize the natural ability of the lymph nodes to educate, activate and amplify cancer-specific T cells. Engineered to coordinate immunity in these uniquely potent sites, the AMP platform was built to amplify the magnitude, potency, quality and durability of the immune response to drive antitumor activity. At the injection site, the platform prevents detrimental payload delivery to systemic circulation, instead guiding the payloads into the lymphatics to promote lymph node delivery. Additionally, it preserves the structural integrity and activity of payloads by preventing any degradation prior to uptake by lymph node resident immune cells. Upon reaching the lymph nodes, the platform optimizes retention and directs the delivery of payloads to key immune cells responsible for the coordination of immune responses, specifically the activation and amplification of cancer-specific immune cells in lymph nodes. Overall, Elicio Therapeutics anticipates that the AMP platform could potentially provide a better quality of life to patients during treatment. The strategy is set apart from other treatments by its ability to activate immune mechanisms directly in the lymph nodes. Enhanced T cell infiltration into tumors, improved T cell expansion and persistence, potent anti-tumor T cell function and wide breadth of response are key attributes with the potential to improve efficacy and reduce the risk of resistance to therapy. Moving forward, Elicio Therapeutics is committed to developing its lymph node-targeting approach for deployment across a range of vaccines, immunomodulators and adjuvants — training the immune system to put the best cells forward to fight a broad spectrum of cancers. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 05, 2024 08:15 AM Eastern Daylight Time

Image

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device

Nexalin Technology

Nexalin Technology CEO Mark White joined Steve Darling from Proactive to share positive results from a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and involved collaboration with the United States Department of Veterans Affairs (VA) San Diego Healthcare System, as well as the Radiology, Psychiatry, and Neurosciences Departments of UC San Diego. mTBI is a significant concern for veterans and the general public, leading to various physical, cognitive, emotional, and behavioral deficits. However, effective treatments for post-concussive symptoms (PCS) are limited, and the underlying pathophysiology is not fully understood. Symptoms of PCS often overlap with those of post-traumatic stress disorder (PTSD), further complicating diagnosis and treatment. The clinical trial was conducted as a randomized, double-blind, placebo-controlled study over an eight-week period, involving two groups: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve sessions of either active or sham tACS over four consecutive weeks, followed by a four-week follow-up period to assess outcomes. The positive results from this study are significant, especially considering the substantial market potential for treatments addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is projected to reach over $7.2 billion by 2032. Nexalin's innovative approach offers promise in addressing the needs of individuals suffering from mTBI, potentially improving their quality of life and providing hope for effective treatment options in the future. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 04, 2024 11:05 AM Eastern Daylight Time

Video